eCase: TD Screening

CE / CME

eCase: Screening for TD: Not Just in Patients With Schizophrenia

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Released: February 28, 2022

Expiration: February 27, 2023

Greg W. Mattingly
Greg W. Mattingly, MD

Activity

Progress
1
Course Completed

This case describes a female patient with a history of bipolar disorder and of receiving atypical antipsychotics. After being hospitalized for a mixed bipolar episode, the patient was prescribed an additional atypical antipsychotic, benzodiazepine, and anticholinergic agent. The patient had several risk factors for developing TD: female sex, treatments with antipsychotics, and anticholinergic use. The patient developed orofacial dyskinetic movements, which in turn increased emotional distress and decreased social functioning. Healthcare professionals should discuss with their patients the risks associated with atypical antipsychotics, including adverse events such as TD, and educate patients on the locations and symptoms of TD. In addition, TD should be screened not only in patients with schizophrenia, but also in patients with depression, bipolar disorder, anxiety disorders, and other psychiatric conditions for which they may be receiving atypical antipsychotic treatment.